Meeting
2023 ASCO Genitourinary Cancers Symposium
The impact of F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states.
Authors
Ali Arafa
University of MInnesota, Minneapolis, MN
Ali Arafa , Aditya Jain , Brad Humphrey , Jerry Froelich , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 63)
DOI
10.1200/JCO.2023.41.6_suppl.63
Abstract #
63
Poster Bd #
B17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Patterns of PSMA PET/CT scan usage for initial staging and recurrence in a multi-centered hospital system.
First Author: Richard Bennett IV
Poster
2023 ASCO Genitourinary Cancers Symposium
18F-DCFPyL PET in first BCR and initial staging: Concordance with conventional imaging.
First Author: Miles Hsu
Poster
2024 ASCO Genitourinary Cancers Symposium
Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
First Author: Michael Leapman
Poster
2024 ASCO Genitourinary Cancers Symposium
Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Frederic Pouliot